Items where authors include "de Bruin, EC"

Article

Howell, SJ, Casbard, A, Carucci, M et al. (14 more authors) (2022) Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. The Lancet Oncology, 23 (7). pp. 851-864. ISSN 1470-2045

Schmid, P, Abraham, J, Chan, S et al. (26 more authors) (2020) Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 38 (5). pp. 423-433. ISSN 0732-183X